Platinum nephrotoxicity.
Platinum coordination complexes have recently been introduced in cancer chemotherapy with considerable success. However, significant nephrotoxicity has emerged as a factor that limits the therapeutic usefulness of these compounds. In this article we review the available knowledge on platinum nephrotoxicity and its prevention that has been derived from both toxicologic studies in animals and clinical trials in human subjects.
D058186:Acute Kidney Injury / Q000139:chemically induced*; D000818:Animals; D002143:Callitrichinae; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D000882:Haplorhini; D006801:Humans; D007275:Injections, Intravenous; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D007677:Kidney Function Tests; D007683:Kidney Tubular Necrosis, Acute / Q000139:chemically induced*; D007684:Kidney Tubules / Q000473:pathology; D007687:Kidney Tubules, Proximal / Q000187:drug effects; D008253:Macaca mulatta; D008297:Male; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011817:Rabbits; D051381:Rats
D002945:Cisplatin